(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., an antibiotics company with a broad development-stage pipeline, today announced the publication of positive preclinical data for delafloxacin highlighting the candidate’s superior infection-site potency against Gram-positive pathogens when compared to moxifloxacin, a leading approved antibiotic in the fluoroquinolone class. The data were published in an online pre-publication of Antimicrobial Agents and Chemotherapy. Delafloxacin is a novel fluoroquinolone antibiotic candidate that offers both IV and oral versatility and has successfully completed three Phase 2 clinical studies in approximately 1,000 subjects.
